OOIR: Observatory of International Research

Papers

(The TQCC of Circulation is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Heart Disease and Stroke Statistics—2021 Update	3365
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association	2625
COVID-19 and Cardiovascular Disease	1236
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association	1036
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association	918
Pulmonary Embolism in Patients With COVID-19	856
Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic	841
Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	819
Cardiovascular Disease in Chronic Kidney Disease	714
The Science Underlying COVID-19	618
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines	614
Myocarditis With COVID-19 mRNA Vaccines	607
Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association	570
Call to Action: Structural Racism as a Fundamental Driver of Health Disparities: A Presidential Advisory From the American Heart Association	548
Obesity Is a Risk Factor for Severe COVID-19 Infection	543
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidel	517
Spectrum of Cardiac Manifestations in COVID-19	429
Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy	420
Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome	412
Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association	407
The Variety of Cardiovascular Presentations of COVID-19	400
2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association	386
Part 1: Executive Summary: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	383
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines	359
Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association	351

Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction	350
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association	341
ST-Elevation Myocardial Infarction in Patients With COVID-19	332
Transcriptional and Cellular Diversity of the Human Heart	323
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clini	323
Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human	303
Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease	301
Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China	296
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque	288
Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association	275
Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation	266
Psychological Health, Well-Being, and the Mind-Heart-Body Connection: A Scientific Statement From the American Heart Association	255
Empagliflozin in Heart Failure	254
Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19	250
Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association	246
Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure	237
Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy	235
Cardiorespiratory Fitness in Youth: An Important Marker of Health: A Scientific Statement From the American Heart Association	233
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)	233
Evidence-Based Assessment of Genes in Dilated Cardiomyopathy	232
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk	229
Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19	226
Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	225
Stem Cell Pluripotency Genes Klf4 and Oct4 Regulate Complex SMC Phenotypic Changes Critical in Late-Stage Atherosclerotic Lesion Pathogenesis	225
Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe	224
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction	219
Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis?	215
Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children	215
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status	213
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association	210
Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association	210
Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device	209
Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990–2017	205
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial	198
Angiotensin Converting Enzyme 2	194
Extracellular Vesicle–Mediated Delivery of Circular RNA SCMH1 Promotes Functional Recovery in Rodent and Nonhuman Primate Ischemic Stroke Models	193
SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes	192
Severe COVID-19 Is a Microvascular Disease	191
Colchicine in Patients With Acute Coronary Syndrome	191
COVID-19, Arrhythmic Risk, and Inflammation	191
Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial	190
Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung	188
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction	188
Fruit and Vegetable Intake and Mortality	187
Microthrombi as a Major Cause of Cardiac Injury in COVID-19	185
Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association	182
Telemedicine Outpatient Cardiovascular Care During the COVID-19 Pandemic	182
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies	178
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction	175
Neonatal Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations	174

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes	172
Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan	170
Part 5: Neonatal Resuscitation: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	169
Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women	167
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function	167
Myocarditis Temporally Associated With COVID-19 Vaccination	166
Myocarditis After BNT162b2 and mRNA-1273 Vaccination	166
Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population	166
Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction	164
Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells	163
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Pr	161
Single-Cell RNA Sequencing Unveils Unique Transcriptomic Signatures of Organ-Specific Endothelial Cells	156
Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis	153
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease	153
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association	153
Single-Cell Transcriptome Analysis Reveals Dynamic Cell Populations and Differential Gene Expression Patterns in Control and Aneurysmal Human Aortic Tissue	149
High-Resolution Transcriptomic Profiling of the Heart During Chronic Stress Reveals Cellular Drivers of Cardiac Fibrosis and Hypertrophy	147
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy	146
How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?	146
Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association	145
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure	143
Diagnosis and Management of Myocarditis in Children	143
Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association	143
Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity	141
Deep Neural Networks Can Predict New-Onset Atrial Fibrillation From the 12-Lead ECG and Help Identify Those at Risk of Atrial Fibrillation–Related Stroke	140
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis	140
High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight Against COVID-19	139
Fate and State of Vascular Smooth Muscle Cells in Atherosclerosis	139
COVID-19 Myocardial Pathology Evaluation in Athletes With Cardiac Magnetic Resonance (COMPETE CMR)	138
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure	137
Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease	136
Cell-Free DNA to Detect Heart Allograft Acute Rejection	135
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis	134
Single-Cell RNA Sequencing Analysis Reveals a Crucial Role for CTHRC1 (Collagen Triple Helix Repeat Containing 1) Cardiac Fibroblasts After Myocardial Infarction	134
Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy	133
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines	133
Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guideline	132
Unexpected Features of Cardiac Pathology in COVID-19 Infection	132
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Gui	131
Blood Pressure Effects of Sodium Reduction	130
A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy	130
Mechanical Complications of Acute Myocardial Infarction: A Scientific Statement From the American Heart Association	130
HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research	130
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease	129
Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial	128
Status of Cardiovascular Health in US Adults and Children Using the American Heart Association’s New “Life’s Essential 8” Metrics: Prevalence Estimates From the National Health and Nutrition Examinati	128
Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales	127
Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations	127
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase	126
Personal-Level Protective Actions Against Particulate Matter Air Pollution Exposure: A Scientific Statement From the American Heart Association	126
Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction	124
Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial	124
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex	124
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF	124
Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes	123
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guide	123
Mortality and Paclitaxel-Coated Devices	122
Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis	122
Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination	122
Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial	121
COVID-19	121
Fontan-Associated Liver Disease	120
COVID-19–Associated Nonocclusive Fibrin Microthrombi in the Heart	120
Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial	120
Therapeutic and Diagnostic Translation of Extracellular Vesicles in Cardiovascular Diseases	119
Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment	118
Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association	118
Ten-Year Differences in Women’s Awareness Related to Coronary Heart Disease: Results of the 2019 American Heart Association National Survey: A Special Report From the American Heart Association	118
Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure	117
Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction	117
Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease	117
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention	117
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36	117
Differentiating COVID-19 Pneumonia From Acute Respiratory Distress Syndrome and High Altitude Pulmonary Edema	116
Assessing and Addressing Cardiovascular Health in LGBTQ Adults: A Scientific Statement From the American Heart Association	115
Endotoxinemia Accelerates Atherosclerosis Through Electrostatic Charge–Mediated Monocyte Adhesion	114
Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association	113
Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis	112
Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019	111
Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults	110

Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries	110
Circular RNA CircMAP3K5 Acts as a MicroRNA-22-3p Sponge to Promote Resolution of Intimal Hyperplasia Via TET2-Mediated Smooth Muscle Cell Differentiation	110
US Mortality Attributable to Congenital Heart Disease Across the Lifespan From 1999 Through 2017 Exposes Persistent Racial/Ethnic Disparities	110
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Cli	110
Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin	109
Altered Hemodynamics and End-Organ Damage in Heart Failure	109
Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure	109
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents	109
Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure])	109
Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement From the American Heart Association	108
ECG-Based Deep Learning and Clinical Risk Factors to Predict Atrial Fibrillation	108
Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex	108
Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association	108
A Unique Population of Regulatory T Cells in Heart Potentiates Cardiac Protection From Myocardial Infarction	108
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy	107
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial	107
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome	106
Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19: Findings From the American Heart Association’s COVID-19 Cardiovascular Disease Registry	105
Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association	105
Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association	104
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials	103
Extracellular Vesicles From Epicardial Fat Facilitate Atrial Fibrillation	103
Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19–Associated Coagulopathy	103
RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-κB Activation and Atherogenesis in Mice	102
Population Trends in Rates of Percutaneous Coronary Revascularization for Acute Coronary Syndromes Associated With the COVID-19 Outbreak	102
Takotsubo Syndrome: Pathophysiology, Emerging Concepts, and Clinical Implications	101
Pathogenic Autoimmunity in Atherosclerosis Evolves From Initially Protective Apolipoprotein B ₁₀₀ –Reactive CD4 ⁺ T-Regulatory Cel	100
Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:	100
Increasing Fatty Acid Oxidation Prevents High-Fat Diet–Induced Cardiomyopathy Through Regulating Parkin-Mediated Mitophagy	100
Cardiovascular Health in American Indians and Alaska Natives: A Scientific Statement From the American Heart Association	99
Randomized Pilot Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography After Cardiac Arrest Without ST-Segment Elevation	99
Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial	99
Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy	98
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary	97
Myocardial Injury in Severe COVID-19 Compared With Non–COVID-19 Acute Respiratory Distress Syndrome	97
Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association	97
Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis	96
Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association	95
Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve Stenosis	95
Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension	95
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease	95
Part 6: Resuscitation Education Science: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	95
Cardiometabolic Traits, Sepsis, and Severe COVID-19	93
Single-Cell RNA Sequencing to Dissect the Immunological Network of Autoimmune Myocarditis	93
Rise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic	92
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER	91
In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine	91
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y ₁₂ Inhibitor in Patients After Percutaneous Coronary Intervention	91
Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement	90
Part 7: Systems of Care: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care	90
Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electroc	90
Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study	90
Heart Regeneration by Endogenous Stem Cells and Cardiomyocyte Proliferation	90
gp130 Controls Cardiomyocyte Proliferation and Heart Regeneration	89
Incidence, Microbiology, and Outcomes in Patients Hospitalized With Infective Endocarditis	89
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial	88
Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70	88
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice	88
Comprehensive Evaluation of Rhythm Monitoring Strategies in Screening for Atrial Fibrillation	87
Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women	87
Comparative Efficacy and Safety of Oral P2Y ₁₂ Inhibitors in Acute Coronary Syndrome	86
Red Blood Cell and Endothelial eNOS Independently Regulate Circulating Nitric Oxide Metabolites and Blood Pressure	86
Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association	86
Long Noncoding RNA MIAT Controls Advanced Atherosclerotic Lesion Formation and Plaque Destabilization	86
An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction	86
The COMPASS Trial	86
General Versus Local Anesthesia With Conscious Sedation in Transcatheter Aortic Valve Implantation	85
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial	84
Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients	84
High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial	84
Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19	84
Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis	83
Coronary Artery Anomalies	83
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention	82
CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic	82
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction	82
Myocardial Infarction in the ISCHEMIA Trial	82
Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections Is Dependent on Streptococcal Species	82
Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease	81
A Novel Endocrine Role for the BAT-Released Lipokine 12,13-diHOME to Mediate Cardiac Function	81
Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19	81
Replacement Myocardial Fibrosis in Patients With Mitral Valve Prolapse	81
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease	81
Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome	81
Adult Basic Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations	80
Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies	79
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial	79
Artificial Intelligence–Enabled Assessment of the Heart Rate Corrected QT Interval Using a Mobile Electrocardiogram Device	78
At the Heart of the Matter	78
Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association	77
Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation	77
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin	77
Medium- and Large-Vessel Vasculitis	76
Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program	76
Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial	76